-
Mashup Score: 10Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology | Research To Practice - 17 day(s) ago
Register for this complimentary event with the “Register Now” button above, which will take you to our Zoom registration page. Join us on Wednesday, May 8 th for this CME/MOC-accredited webinar 5:00 PM – 6:00 PM ET Faculty Justin F Gainor, MD Director, Center for Thoracic Cancers Program Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Karen Reckamp,
Source: m.researchtopractice.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 6Second-Line Pembrolizumab Plus Ramucirumab Extends OS Over Standard of Care in Advanced NSCLC - 2 year(s) ago
Findings from the Lung-MAP nonmatched substudy S1800A indicate that second-line pembrolizumab plus ramucirumab demonstrate a potential survival benefit for patients with advanced non–small cell lung cancer (NSCLC) with immune checkpoint inhibitor resistance compared with standard-of-care regimens that included docetaxel and ramucirumab (Abstract 9004).
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
It’s been refreshing to see colleagues and discuss the data at #ASCO2022 We are excited to see coverage #ASCODailyNews of the OS benefit for previously treated NSCLC with ramucirumab and pembrolizumab in S1800A @ASCO https://t.co/yjnkqayd1N
-
-
Mashup Score: 10Event Registration - 2 year(s) ago
Clinicalcare option Login Registration.
Source: www.clinicaloptions.comCategories: Latest Headlines, Oncologists2Tweet-
I’ll be at #ASCO22 presenting the latest treatment options for common + less common targetable #biomarkers for advanced #NSCLC: #EGFR, KRAS, and #HER2 alongside @Todd_M_Bauer @NarjustDumaMD @ReckampK. Join us Sat June 4 in Chicago #lungcancer https://t.co/OYwJG8tjr9
-
Join us for the Year in Review Live Webinar | Targeted Therapy for Non-Small Cell Lung Cancer Edition on May 8, 4:30-6pm ET. Dr. Justin Gainor and I will discuss the latest updates with Dr. Neil Love to improve patient care and outcomes. #LCSM https://t.co/1FqK4JD3dB